Emfilermin
Also known as: BMS‑986036, Emifermin, PEG‑FGF21
Source Emfilermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Emifermin (BMS‑986036) is a PEGylated recombinant analog of human FGF21 being studied for non‑alcoholic steatohepatitis (NASH) and metabolic disorders. It is administered subcutaneously and has shown reductions in liver fat and fibrosis markers in early‑phase trials.
Mechanism of Action
PEGylated FGF21 analog that activates the FGFR1c/KLB receptor complex, promoting metabolic signaling pathways that improve lipid metabolism, glucose homeostasis, and hepatic fibrosis.
Routes of Administration
Goals & Uses
- Improvement of dyslipidemiaMetabolicLow
- NASH treatmentHepaticModerate
- Reduction of hepatic steatosisMetabolicModerate
Contraindications
- Severe hepatic impairment (Child‑Pugh C)Liver DiseaseModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- HeadacheNeurologicUncommonPain in the head or upper neck
- Elevated LDL cholesterolLaboratoryUnknown
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Cytochrome P450 substratesLow
Population Constraints
- Pediatric patients (<18 years)AgeAbsolute
- Renal impairment (eGFR <30 mL/min)RenalRelative
Regulatory Status
- European UnionInvestigationalClinical development under EMA oversight.
- United StatesInvestigationalPhase 2/3 trials ongoing for NASH.
Currently in Phase 2/3 clinical development; not approved in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Emfilermin?
Emifermin (BMS‑986036) is a PEGylated recombinant analog of human FGF21 being studied for non‑alcoholic steatohepatitis (NASH) and metabolic disorders. It is administered subcutaneously and has shown reductions in liver fat and fibrosis markers in early‑phase trials.
What is Emfilermin used for?
Emfilermin is educationally associated with: Improvement of dyslipidemia, NASH treatment, Reduction of hepatic steatosis. Educational only — not medical advice.
How is Emfilermin administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Emfilermin?
Reported adverse effects include: Headache, Elevated LDL cholesterol, Nausea, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Emfilermin?
Recorded contraindications: Severe hepatic impairment (Child‑Pugh C), Pregnancy. Consult a qualified clinician before use.